Nimura Yuji
Aichi Cancer Center.
Gan To Kagaku Ryoho. 2007 Jul;34(7):993-6.
Although surgical techniques for pancreatic cancer have developed in a high level, the treatment results have not been improved and the 5 year survival rates after curative operation has been about 15% in Japan. Retrospective studies on extended lymphadenectomy for ductal adenocarcinoma of the head of the pancreas revealed that extended surgery prolonged the survival for resected patients. These studies have been reported mainly from Japan and followed by similar retrospective studies from Japan and European countries which showed same advantageous results in extended lymphadenectomy or did not reveal any advantages in this aggressive approach. Finally, the clinical advantages of extended lymphadenectomy for pancreatic cancer was denied by several RCTs from Italy and U.S.A. Although usefulness of radio/chemotherapy has been controversial, adjuvant chemotherapy with gemcitabin significantly prolonged the patients' survival after curative pancreatectomy. Further development of multidisciplinary treatments for pancreatic cancer is expected.
尽管胰腺癌的外科手术技术已发展到很高水平,但治疗效果并未得到改善,在日本,根治性手术后的5年生存率约为15%。对胰头导管腺癌扩大淋巴结清扫术的回顾性研究表明,扩大手术延长了切除患者的生存期。这些研究主要来自日本,随后日本和欧洲国家也进行了类似的回顾性研究,这些研究表明扩大淋巴结清扫术有相同的优势结果,或者在这种积极的手术方式中未显示出任何优势。最后,意大利和美国的几项随机对照试验否定了胰腺癌扩大淋巴结清扫术的临床优势。尽管放化疗的有效性一直存在争议,但吉西他滨辅助化疗显著延长了根治性胰腺切除术后患者的生存期。期待胰腺癌多学科治疗的进一步发展。